Tiziana Life Sciences (NASDAQ:TLSA) soars 26% premarket on the heels of the announcement that the USPTO has granted the company a patent on use and methods of treatment of Crohn’s disease with Foralumab, a fully human monoclonal antibody, and all other anti-CD3 monoclonal antibodies (mAb).
The composition-of-matter and use patent will be published on September 1 as Patent No. 10,759,858.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.